CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Lamotrigine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00419003
NCT00419003Phase 4Completed
CompareCT.gov

Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression

Baylor College of Medicine·interventional·Posted Jan 5, 2007·Updated Jul 31, 2019

In Brief

A Phase 4 clinical trial evaluating Lamotrigine, Ketamine, and 1 other intervention for Major Depression. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression, National Center for Research Resources (NCRR)

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 5, 2007
Enrollment StartDec 1, 2006
Primary CompletionJul 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.5 years ago

Interventions

Lamotriginedrug

anticonvulsant medication

Ketaminedrug

subanesthetic dose of NMDAR antagonist

Riluzoledrug

glutamate release inhibitor